By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Takeda Pharmaceutical and Kyoto University today announced a five-year deal focused on the development of new central nervous system-acting drugs for obesity and schizophrenia.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.
The New York Times editorial board weighs in on scientific research misconduct.
The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.
The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.